Pain/Inflammation Featured Articles
-
New Patch Technology Will Help Scintilla Treat Pain
8/16/2016
Pain management company Scintilla Pharmaceuticals has announced it will acquire SCILEX Pharmaceuticals to bolster its pain management business. SCILEX is engaged in the development and commercialization of products focused on the treatment of pain. Its lead product candidate, ZTlido, is a branded lidocaine patch formulation being developed for the treatment of postherpetic neuralgia, the chronic pain that sometimes develops with shingles.
-
Iroko Uses Event Monitoring System To Power Phase 3 Trial Of VIVLODEX
6/13/2016
In a recently completed Phase 3 trial, efficacy was demonstrated in patients with osteoarthritis pain who were treated with VIVLODEX, a low-dose SoluMatrix NSAID product. The Medication Event Monitoring System (MEMS) was used in the study to accurately track when patients required additional pain-relieving medication and to show that patients using VIVLODEX required less rescue pain medication.
-
France Tragedy Reminds Us Phase 1 Researchers Must Live With Tragic Results
3/29/2016
The recent clinical research tragedy in France that resulted in the death of one patient and the hospitalization of four others shocked many who work in the clinical research space. The adverse effects experienced by the previously healthy patients, reportedly involving deep brain bleeds, were both rare and disturbing.
-
Will Cyclobenzaprine Be A Solution For Fibromyalgia Patients?
2/22/2016
Seth Lederman, M.D. has worked with many patients with fibromyalgia as a physician, and knows they have waited long enough for relief from its symptoms. “Those symptoms can quickly take over their lives,” he says. “Fibromyalgia is considered to be a pain disorder but it’s much more than that.”
-
Is There A Link Between The France Tragedy And Legal Highs?
1/20/2016
By now you have heard about the tragic clinical trial in France that has resulted in the death of one person and the hospitalization of four others. While full details of what caused the fatal death of a healthy man are still not available, we do know the trial was likely testing an FAAH-inhibitor. Maia Szalavitz, writing on the website Vice.com, says this should be a wakeup call to some legal substance users in the U.S.
-
How Do I Get My Compound Into Phase I?
4/2/2014
The primary challenge for pharmaceutical and biotechnology companies in developing their drugs is to carefully assess the relationship between efficacy and toxicity prior to entering into human clinical trials. By Dr. Scott E. Boley and Greg Ruppert
-
Your CRO Just Acquired Another CRO – Now What?
7/27/2013
A year ago, Wendel Barr, CEO of CRO Synteract, was frustrated. His company was profitable, he had talented personnel, Synteract was managing a wide variety of projects, and his clients were satisfied with their level of service. Despite this success, his potential to grow the business was constrained. Synteract was a U.S.-based firm with limited presence overseas. As a result, his company often found itself forced to leave money on the table, especially as its customers moved to larger, Phase 3 trials. “It became clear to us that in order to provide the range of services our customers required, we had to have more offices in Europe, beyond our office in Prague,” he says. “If you want to be a full service provider from Phase 1 to Phase 4, you have to be global.”
-
Former Big Pharma R&D Exec Shares Thoughts On Outsourcing
5/2/2013
Jim Hauske is President and founder of Sensor Pharmaceuticals, a company focused on the nexus of inflammation and metabolic disease. A virtual company, Sensor has established business relationships with AMRI, Absorption Systems, MPI, RenaSci, Ricerca and SciLucent. These relationships provide the means to synthesize, screen and assess, in disease models, new chemical entities designed by Sensor. The company has pre-clinical compounds representing several chemo types versus GPR119, GPR120 and TLR-4. All these molecules have demonstrated in vivo activity in relevant animal disease models.
-
Repurposing And Rescuing Pharmaceutical Drugs
4/26/2013
Repurposing marketed drugs or rescuing compounds that failed in clinical trials offers entrepreneurs the potential to replenish pipelines with reduced risk and time.
-
Outsourcing Insights From The President Of A Virtual Drug Discovery Company
4/16/2013
Carolyn Green, is the President and Director for Atreaon, Inc., a privately held biopharmaceutical company developing a novel engineered protein called Atsttrin, for the treatment of inflammatory diseases such as rheumatoid arthritis. Having recently completed a $20 million Series A financing to support the pre-clinical development of Atsttrin, Green took time out from her busy schedule to share some of her thoughts and insights regarding the outsourcing of clinical research.